The world’s first online collaboration platform repurposing research

25 project repurposing

research portfolioSocial Finance

InitiativeCreating “pay for

success” repurposing

economics in the UK

5 Programs to Leverage Successes and Overcome Challenges

The Low Profit Pharma Co.Bringing low profit

commercializable generic drug repurposing to market with the

support of Impact Investors

The Generic Drug Companies Initiative

Partner with generic drug companies to fund generic drug repurposing

research based on potential overall increases in the sales of generic drugs.

Ongoing

Feasibility

Possibility

Feasibility-Low Profit Pharma Company

Huge Global Problem – Too many unsolved diseases, too few therapeutic breakthroughs, the ones that come are too slow to get to patients and too expensive.  Solution –Many therapeutic opportunities through generic drug repurposing have huge financing challenges. Innovation – create an investment vehicle for Impact Investors – a low profit drug repurposing company to identify repurposing opportunities across all disease classes that have potential commercial return and patient impact, but are below industry market returns.

Cures Within Reach is in an ideal position to do this work – we have the platform, networks, experience and success stories. CWR has already identified a set of repurposing projects that are LoPro candidates. 

Feasibility-Social Impact Bond Initiative

Problem-Industry does not fund generic drug repurposing for current dosage and formulation because there is little profit potential.

Solution-Create incentive for investors to finance life-saving Repurposing Research through a Social Impact Bond (SIB) in which the government pays for improved healthcare outcomes and reduced healthcare costs through drug repurposing.

CWR is currently developing this SIB concept with the British Government and beginning to talk with the UN and others about a global SIB initiative

Feasibility-Social Impact Bond Initiative

Feasibility-Social Impact Bond ROI

# of clinical

trials

Average cost per clinical

trial

Total Rediscovery

Research Costs

Potential success

rate

# of "new" treatments

created

# of patients who have one disease with a

"new treatment

Projected annual

healthcare $ saved/average

patient

Total potential 5 year savings for all

patients with these diseases

% patients actually

using the "new"

treatments

healthcare $ saved on this sub-

population of patients AFTER

repaying investors

200 250,000 $50,000,000 10% 20 3000 $10,000 $600,000,000 10% $10,000,000

200 250,000 $50,000,000 15% 30 4000 $20,000 $2,400,000,000 10% $190,000,000

200 250,000 $50,000,000 20% 40 8000 $30,000 $9,600,000,000 10% $910,000,000

200 250,000 $50,000,000 25% 50 15000 $40,000 $30,000,000,000 10% $2,950,000,000

200 250,000 $50,000,000 30% 60 32000 $50,000 $96,000,000,000 10% $9,550,000,000

Possibility-The Generic Drug CompaniesRepurposing Partnership

Economic Innovation – Partner with generic drug companies to fund generic drug repurposing based increases in the sales of generic drugs. It makes sense –Every new repurposed generic drug use would improve healthcare outcomes and increase revenue to generic drug companies. The short-term investment is small and the long-term return is large. CWR can promote off-label uses even if a drug company cannot. Generic drug companies information about off-label use of drugs can inform researchers to propose additional repurposed uses. This is a strong marketing/PR opportunity for generic drug companies, showing their commitment to creating effective low cost treatments for patients.

For more information, see

www.cureswithinreach.orgwww.cureaccelerator.orgTwitter.com/CuresWReach

Facebook.com/P4Cures

Or contact:

Dr. Bruce BloomPresident and CSO

Bruce@cureswithinreach.org847-745-1245